Widely used:Recently Viewed
Clear All$8.02
$0.18
(2.30%)
As on 28-Apr-2025 16:10EDT
Today’s Range
52 Week Range
Liquidity
Market cap
$457 Mln
P/E Ratio
--
P/B Ratio
0.64
Industry P/E
--
Debt to Equity
0.61
ROE
-0.6 %
ROCE
-43.87 %
Div. Yield
0 %
Book Value
13.8
EPS
-10.54
CFO
$-982.01 Mln
EBITDA
$-4,847.20 Mln
Net Profit
$-5,082.46 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Ginkgo Bioworks Holdings Inc. Class A (DNA)
| -18.33 | 21.70 | -32.15 | -76.69 | -61.19 | -- | -- |
|
BSE Sensex*
| 2.59 | 3.69 | 5.76 | 8.88 | 11.75 | 20.11 | 11.35 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Ginkgo Bioworks Holdings Inc. Class A (DNA)
| -85.24 | 0.00 | -79.66 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.44 | 10,315.11 | 21.27 | 23.13 | |
| 298.18 | 8,705.27 | 22.77 | 66.44 | |
| 27.46 | 10,589.59 | -- | -28.77 | |
| 106.46 | 10,559.67 | 32.44 | 14.16 |
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell programming in the United States. It operates through Cell Engineering and Biosecurity segments. The company offers cell engineering research and development... solutions, as well as cell engineering tools comprising functional genomics and antibody developability Datapoints services, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. The company serves the pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. Address: 27 Drydock Avenue, Boston, MA, United States, 02210 Read more
Founder, CEO & Director
Dr. Jason Kelly
Founder
Mr. Thomas Knight Jr.
Headquarters
Boston, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Ginkgo Bioworks Holdings Inc Class A (DNA) stood at $ 1,377 Mln as on 31-Dec-24
The share price of Ginkgo Bioworks Holdings Inc Class A (DNA) is $8.02 (NYSE) as of 28-Apr-2025 16:10 EDT. Ginkgo Bioworks Holdings Inc Class A (DNA) has given a return of -61.19% in the last 3 years.
Ginkgo Bioworks Holdings Inc Class A (DNA) has a market capitalisation of $ 457 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Ginkgo Bioworks Holdings Inc Class A (DNA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Ginkgo Bioworks Holdings Inc Class A (DNA) and enter the required number of quantities and click on buy to purchase the shares of Ginkgo Bioworks Holdings Inc Class A (DNA).
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell programming in the United States. It operates through Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics and antibody developability Datapoints services, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. The company serves the pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. Address: 27 Drydock Avenue, Boston, MA, United States, 02210
The CEO & director of Dr. Jason Kelly. is Ginkgo Bioworks Holdings Inc Class A (DNA), and CFO & Sr. VP is Mr. Thomas Knight Jr..
There is no promoter pledging in Ginkgo Bioworks Holdings Inc Class A (DNA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Ginkgo Bioworks Holdings Inc. Class A (DNA) | Ratios |
|---|---|
|
Return on equity(%)
|
-60.34
|
|
Operating margin(%)
|
-241.11
|
|
Net Margin(%)
|
-240.94
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Ginkgo Bioworks Holdings Inc Class A (DNA) was $0 Mln.
